CA-MAWI-DNA-TECHNOLOGIES
11.5.2021 15:02:10 CEST | Business Wire | Press release
Mawi DNA Technologies, a biotechnology company focusing on the development of innovative technologies for biosampling, announces that MagBio Genomics has successfully developed an automated RNA purification method for iSWAB-RNA v2 on the Thermofisher KingFisher™ Flex platform with its HighPrep™ Total RNA Isolation Kit - iSWAB™.
Mawi DNA Technologies’ iSWAB-RNA v2 allows for non-invasive self collection, concentration, and stabilization of intact buccal cells and/or any mammalian cells collected with a swab or cytobrush. It enables up to four weeks of real-time ambient stabilization of total RNA from the point of collection to processing. The high-quality RNA extracted from stabilized iSWAB-RNA v2 samples is suitable for gene expression applications such as real-time quantitative PCR, reverse transcription PCR, microarrays, northern blot analysis, nuclease protection assays, cDNA library construction and RNA-seq.
“Collaborating with MagBio Genomics to optimize their HighPrep™ Total RNA Plus Kit-iSWAB™ for iSWAB-RNA v2 was a no-brainer for us, especially because it provides a great option for our high throughput end users like pharma and CROs,” said Dr. Bassam El-Fahmawi, President and CTO, Mawi DNA Technologies. “Partnerships with leaders in nucleic acid purification chemistries with a global presence, such as MagBio Genomics, are increasing worldwide access of our sample collection technologies, which results in better understanding of health and wellness at a global rather than at a regional level.” El-Fahmawi said that due to increased sample sizes in cohort genetic population studies, there is an increasing need for automated RNA purification solutions. The MagBio HighPrep Total RNA Plus Kit-iSWAB™ simplifies this research step, which can be labor-intensive.
“MagBio has successfully developed and optimized the HighPrep™ Total RNA Isolation Kit-iSWAB™ for extraction of total RNA from iSWAB-RNA v2 samples on Thermofisher KingFisher™ Flex Purification System,” said Dr. Mothomang Mlalazi-Oyinloye, Associate Scientific Director, MagBio Genomics. “This new method is being used by a major pharmaceutical company to process iSWAB-RNA v2 samples for elucidation of molecular mechanisms of cancer development. With this automated protocol, 96 samples can be run in less than one hour.” She added that the extracted RNA is of high purity and quality and is compatible with complex and sensitive assays. RNA yields up to 1ug per sample are obtained (Qubit RNA Broad Assay).
“We are expanding our automated methods library to include the most commonly used lab automation systems,” Dr. Mlalazi-Oyinloye said. “iSWAB-RNA v2 is the non-invasive sample collection alternative to venipuncture and tissue biopsy our fellow researchers have been looking for which maintains RNA integrity especially during long transit times. MagBio Genomics is all about making the next generation sequencing workflow better. We developed an automated method for simplifying RNA purification from iSWAB-RNA v2 samples using our HighPrep™ Total RNA Plus Kit-iSWAB™,” said Dr. Hyacinth Ntchobo, CEO, MagBio Genomics. He added that when used in combination, Mawi’s iSWAB-RNA v2 collection technology and MagBio Genomics’ purification chemistry provide an efficient workflow for high throughput purification of high-quality RNA for demanding downstream applications.
About MagBio Genomics Inc.
MagBio Genomics is a global company that develops and commercializes magnetic bead-based products for nucleic acid isolation including biomarkers as tools for liquid biopsy genomic research. The current focus encompasses products that cover the complete sample preparation for NGS; from allowing safeguarding integrity of bio-samples, efficient isolation of circulating biomarkers to target enrichment from biological samples. Products are applied to human genetic research including cancer genomic studies and non-invasive prenatal testing (NIPT).“WE SIMPLY MAKE NGS BETTER.” For more information, visit http://www.magbiogenomics.com .
About Mawi DNA Technologies
Mawi DNA Technologies has developed and commercialized the iSWAB technology, an innovative system for collection of biosamples. Flagship product iSWAB-DNA has gained significant market traction due to its ability to be used for animals and all human population segments from infants to the elderly, with robust DNA yield and low bacterial DNA content. Mawi DNA has established relationships with children’s hospitals for neonatal screening and has an extensive global network of international distributors to market and sell iSWAB products. For more information, visit http://www.mawidna.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210511005456/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
mimik Operationalizes Agentic AI on the AMD Ryzen™ AI Embedded X100 Series23.7.2026 20:30:00 CEST | Press release
mimik today announced mimOE™ Embedded Edition, a package of its Agentix Operating Engine and a set of purpose-built tools for the AMD Ryzen™ AI Embedded X100 Series processor, the newest processor in a family designed for physical AI, autonomous systems, and industrial automation. Available to download today, mimOE Embedded Edition gives OEMs, tier-1 suppliers, system integrators, and agent developers the path to operationalize Agentix-Native systems (aka Agentic AI), in which autonomous agents can reason, coordinate, and act directly on devices, from PoC to scaled operations with certainty. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260723555565/en/ Agentic AI operations are both CPU and GPU bound. Enterprises can now scale with certainty. Generative AI has centered on the GPU. Agentix-Native systems must spread the work. In a real multi-agent workflow traced by mimik, more than 80 percent of operations were CPU work: d
U.S. Federal Court Permanently Bans 19 Online Sellers of Fake Urolithin A Supplements and Awards $5.3 Million in Damages to Timeline23.7.2026 16:27:00 CEST | Press release
Default judgment follows Timeline’s independent laboratory testing showing products sold under 19 online brands contained no detectable Urolithin A, or far less than advertised Timeline (Amazentis SA), the Swiss life-sciences company that pioneered the postbiotic ingredient Urolithin A and its branded form Mitopure®, together with its U.S. subsidiary Timeline Longevity, Inc., announced today that the U.S. District Court for the District of Massachusetts has granted the companies’ motion for default judgments and permanent injunctions against 19 online sellers found to have marketed and sold nutritional supplements falsely advertised as containing Urolithin A. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722951066/en/ Timeline longevity supplement powered by Mitopure; proprietary, highly pure Urolithin A. The order, entered July 15, 2026 by Judge Myong J. Joun in Amazentis SA et al. v. The Partnerships and Unincorporated
TestMu AI Introduces the Source-to-Verdict Loop in Kane CLI, Carrying Every Requirement to a Ship Decision With Portable Proof23.7.2026 15:45:00 CEST | Press release
Kane CLI now takes a requirement all the way to a ship-or-hold verdict, designing the tests, running them in a real browser, and emitting an open .evidence proof pack that teammates, AI agents, and auditors can all verify, with no server or dashboard required TestMu AI (formerly LambdaTest), the world's first Agentic AI-powered Quality Engineering platform, introduced a source-to-verdict loop in Kane CLI, its natural-language testing tool. Building on Kane CLI's evolution from a browser automation tool, the loop carries a product requirement to a ship decision, writing the tests, running them in the local browser, collecting the proof, measuring coverage from what actually happened, and returning a verdict. As AI agents write, run, and fix tests, a green checkmark is no longer enough: a step that checks nothing passes, a test written against a spec that changed weeks ago passes, and an agent that says “done” without the click ever landing passes. Empty green and earned green are the sa
Norway’s health system adopts Wolters Kluwer UpToDate Enterprise Edition23.7.2026 15:30:00 CEST | Press release
Enterprise Clinical Decision Support solution available to 30,000 clinicians in more than 50 Norwegian hospitals Wolters Kluwer Health announced that Norway’s health system has renewed its adoption of UpToDate Enterprise Edition, a market-leading Clinical Decision Support (CDS) solution, for its nationwide health system which includes over 50 public hospitals and 11,000 beds in over 20 trusts. This extends a 15 year partnership with Helsebiblioteket, now part of the Norwegian Institute of Public Health (NIPH). Helping clinicians on a national scale Kjell Tjensvoll, Team Leader for Helsebiblioteket said, ‘‘Providing frontline teams with easy access to the latest medical knowledge is vital in reducing unwarranted variation and improving patient care on a national scale. UpToDate Enterprise Edition enables this, and we are delighted to strengthen our relationship with Wolters Kluwer and provide continued support for clinicians across the country.’’ UpToDate Enterprise Edition was selected
Boyd Watterson Global Names John Creswell Global Chief Client Officer to Accelerate Global Growth and Client Engagement23.7.2026 15:00:00 CEST | Press release
Veteran investment management executive will lead global sales, client engagement and marketing as Boyd Watterson Global continues expanding its global alternatives platform across real estate, infrastructure, and debt strategies. Boyd Watterson Global today announced the appointment of John Creswell as Global Chief Client Officer, a newly created senior leadership role that reflects the firm's continued investment in growth and its evolution into a leading global alternatives investment platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722823117/en/ John Creswell has joined Boyd Watterson Global as Global Chief Client Officer, a newly created role overseeing global sales, client engagement and marketing across the U.S., Europe and APAC. In this role, Creswell will oversee global sales, client engagement and marketing efforts across the United States, Europe and APAC, helping investors access the firm's capabilitie
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
